As Oxford Immunotec Global Plc (OXFD) Valuation Declined, Endurant Capital Management LP Has Lifted Its Position by $6.85 Million

Oxford Immunotec Global PLC (NASDAQ:OXFD) LogoInvestors sentiment decreased to 1.26 in Q2 2019. Its down 0.21, from 1.47 in 2019Q1. It is negative, as 16 investors sold OXFD shares while 22 reduced holdings. 21 funds opened positions while 27 raised stakes. 24.31 million shares or 4.95% more from 23.16 million shares in 2019Q1 were reported. Utd Svcs Automobile Association owns 165,600 shares for 0.01% of their portfolio. Magnetar Limited owns 54,477 shares or 0.02% of their US portfolio. Barclays Public Limited reported 105,387 shares. Citigroup has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 17,945 shares. Essex Investment Mngmt Co Ltd reported 143,927 shares. Lmr Ltd Liability Partnership has invested 0.01% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Cortina Asset Mngmt Limited Liability Company has invested 0.38% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Neuberger Berman Ltd Liability Company has 128,100 shares for 0% of their portfolio. Bnp Paribas Arbitrage reported 2,897 shares. Cubist Systematic Strategies Ltd Llc owns 23,702 shares or 0.01% of their US portfolio. 94,354 were reported by Jpmorgan Chase &. Signaturefd Lc owns 80 shares or 0% of their US portfolio. Jane Street Group Incorporated Limited Liability Corp stated it has 40,465 shares or 0% of all its holdings. Polar Ltd Liability Partnership accumulated 2.57M shares. Consonance Capital Management LP reported 2.34 million shares.

Endurant Capital Management Lp increased its stake in Oxford Immunotec Global Plc (OXFD) by 513.33% based on its latest 2019Q2 regulatory filing with the SEC. Endurant Capital Management Lp bought 526,643 shares as the company’s stock declined 19.58% . The institutional investor held 629,236 shares of the in vitro & in vivo diagnostic substances company at the end of 2019Q2, valued at $8.66M, up from 102,593 at the end of the previous reported quarter. Endurant Capital Management Lp who had been investing in Oxford Immunotec Global Plc for a number of months, seems to be bullish on the $371.07M market cap company. The stock increased 1.32% or $0.18 during the last trading session, reaching $13.83. About 48,649 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 8.68% since September 13, 2018 and is uptrending. It has outperformed by 8.68% the S&P500.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Nasdaq.com which released: “AMN Healthcare (AMN) Closes Advanced Medical Acquisition – Nasdaq” on June 18, 2019, also Globenewswire.com with their article: “Oxford Immunotec Schedules Second Quarter 2019 Earnings Release and Conference Call for August 6, 2019 – GlobeNewswire” published on July 18, 2019, Nasdaq.com published: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Globenewswire.com and their article: “Oxford Immunotec Reports First Quarter 2019 Financial Results – GlobeNewswire” published on May 09, 2019 as well as Nasdaq.com‘s news article titled: “Here’s Why You Should Hold on to Stryker (SYK) Stock Now – Nasdaq” with publication date: June 19, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.